GSK “Sincerely Apologizes” And Accepts Record $485 Million Fine For China Bribes
This article was originally published in PharmAsia News
The ticket has finally been handed out. Amid a record fine for bribery, GSK says that it remains fully committed to China.
You may also be interested in...
Seven years after a major shift in how the company compensated its sales force, the UK major has done a U-turn and is adapting pay packages for some specialty care reps.
Major Chinese biopharma contract services group WuXi Biologics' share price plummeted after it said external factors would contribute to it missing original revenue targets this year in multiple areas.
Although the spread of HIV/AIDS appears to be largely under control in China, increasing infections among the elderly are causing concern due to a range of risk factors, while domestic firms move to expand their drug offerings.